PEHA’s Net Profit Surges 511% in the First Half of 2026

JAKARTA, August 29, 2026 – PT Phapros Tbk (PEHA), part of the State-Owned Pharmaceutical Holding and Danantara Indonesia, continued to record positive financial performance growth in the first half of 2026. The Company’s net profit for the January–June 2026 period surged significantly by 511.01% to Rp14.97 billion, compared with Rp2.45 billion in the same period of the previous year.

Intan Abdams Katoppo, President Director of PT Phapros Tbk, explained that Phapros’ performance growth in the first half of 2026 was supported by higher sales, improved gross profit margins resulting from improvements in the product portfolio, and greater operational efficiency in production processes at the Company’s manufacturing facility. According to her, this strong performance was achieved through the implementation of the Company’s strategies, including strengthening sustainable financial health through more disciplined cost control, strategies to improve customer satisfaction, portfolio enhancement, transformation of systems and business processes, as well as optimization of human resources and corporate culture.

“Phapros has successfully maintained its positive financial performance growth trend. We are optimistic that Phapros’ profit will continue to grow by more than double digits through the end of 2026. Therefore, we remain consistent in implementing the Company’s strategies to continuously strengthen innovation and profitability, enabling us to deliver added value to shareholders and contribute to the health of the Indonesian people,” said Intan on Saturday (August 29, 2026).

The surge in the national pharmaceutical company’s net profit was driven by a 5.37% increase in sales to Rp482.85 billion in the first half of 2026, compared with Rp458.22 billion in the same period last year. The increase in sales was supported by stronger sales of high-margin products.

In addition, Phapros successfully improved efficiency by lowering its cost of goods sold (COGS) during the January–June 2026 period. The COGS-to-sales ratio as of June 2026 stood at only 49%, compared with 52% in the same period of the previous year, representing a 3% improvement in the cost ratio. This indicates that the 5.37% year-on-year increase in sales outpaced the increase in COGS, resulting in an improvement in gross profit margin to 50.4%, compared with 48.0% in the first half of 2025.

Phapros also successfully strengthened its cash position. The Company’s cash and cash equivalents as of June 30, 2026 amounted to Rp162.47 billion, an increase of 215.6% compared with Rp51.49 billion as of June 30, 2025. Phapros’ total assets as of June 30, 2026 increased by 4.66% to Rp1.45 trillion, compared with Rp1.39 trillion at the end of 2025 (December 31, 2025).

Driving Innovation to Strengthen Performance, Phapros Prepares New Product

In addition to recording growth in financial performance, Phapros continues to strengthen its growth strategy through product portfolio development. The Company is currently preparing for the production of a new powdered product from the nonsteroidal anti-inflammatory drug (NSAID) therapeutic class, specifically designed to help relieve pain and inflammation in dental cases. The product is intended to strengthen Phapros’ already well-established dental product line, which includes Pehacaine, an anesthetic product.

The new product is currently in the production preparation stage and will soon enter the commercialization phase, with its launch targeted for the fourth quarter of 2026. This innovation represents one of Phapros’ initiatives to expand the range of products available to the public while creating new growth opportunities for the Company.

“New product development is part of Phapros’ commitment to continuously innovate and respond to the needs of the public. We hope that this product can be launched soon and make a positive contribution, both to public health and to the Company’s business growth,” Intan concluded.

Strengthening Exports to Several Countries

In addition to its domestic business, Phapros has been developing its export business since 2014. To date, Phapros has exported its products to several countries, including Cambodia, the Philippines, Myanmar, Nigeria, Peru, and Papua New Guinea. Its key export products, which have been marketed internationally for nearly a decade, include analgesics, anti-tuberculosis (anti-TB) products, multivitamins, motion sickness medicines, and antibiotics.

Throughout the third and fourth quarters of 2026, the Company also plans to ship export products to several countries, including the Philippines, Timor-Leste, and Cambodia, with targeted export sales reaching Rp5 billion.

“Going forward, the Company will continue to target double-digit growth in export sales to support its domestic business, including by increasing the number of prospective buyers and expanding its product lines.”